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
REACTIVE CARBONYL SPECIES, 
ADVANCED GLYCATION END PRODUCTS, 
AND AGE-RELATED DISEASES
Non‑enzymatic modifications of proteins have been impli-
cated in the pathogenesis of diabetes, atherosclerosis, neuro-
degenerative diseases, and normal aging.[1,2] The modifications 
can arise from direct exposure to reactive oxygen, chlorine, or 
nitrogen species, and from reaction with low‑molecular‑weight 
reactive carbonyl species (RCS), which originate from a multi-
tude of mechanistically related pathways, like glycation, sugar 
autoxidation, lipid peroxidation, and UV‑photodamage. The 
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accumulation of various RCS such as glyoxal (GO), methylg-
lyoxal (MGO) derived from carbohydrates or lipids, as well as 
their subsequently induced protein modifications are proposed 
to constitute a state of “carbonyl stress.”[3] These RCS are 
responsible for the formation of advanced glycation end prod-
ucts (AGEs) and advanced lipoxidation end products (ALEs), 
and their roles in the development of various aging‑related 
diseases have been increasingly recognized.[4] Higher levels 
of RCS were observed in the plasma of diabetes patients than 
in the plasma of healthy people.[5] Therefore, decreasing the 
levels of dicarbonyl compounds, and consequently, inhibiting 
the formation of AGEs would be a useful approach to prevent 
the development of diabetic complications. There is thus a 
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prompt need to develop effective strategies to protect from 
RCS‑associated pathogenic conditions, and this will remain 
one of the major research directions that merit global intention. 
A very limited number of chemical agents have been found 
to suppress or prevent excessive generation and accumula-
tion of cellular RCS, and their therapeutic potential has been 
recognized only recently. These compounds exert their action 
by interfering with different phases of the reaction cascades, 
such as by acting as antioxidants, by chelating metal ions, or by 
directly trapping RCS. As free radical‑mediated and oxidative 
reactions are known to be involved in the process of glycation 
and lipoxidation, it is not a surprise that antioxidants may be 
effective inhibitors of glycation and/or lipoxidation in in vitro 
assays. However, numerous clinical trials have failed to provide 
conclusive evidence for the efficacy of antioxidant therapy in 
several chronic diseases. These findings have created doubt 
about the effectiveness of chemical agents that behave solely 
as antioxidants in alleviating carbonyl stress. An integration of 
these previous findings and information regarding the forma-
tion pathways of RCS, AGEs, and ALEs has enabled us to put 
forward the hypothesis that chemical agents possessing dual 
mechanisms of action, namely antioxidant and RCS‑trapping 
activities, are likely to be more promising candidates for de-
veloping into disease‑preventive agents/pharmaceutical leads 
for age‑related diseases.
TRAPPING OF RCS BY DIETARY 
PHYTOCHEMICALS
In our studies as well as those of other laboratories, various 
natural extracts and phytochemicals have been evaluated for their 
effects on RCS‑induced modification of protein structure. Yet, 
only a very limited number of natural products have demonstrated 
RCS‑trapping capacity.[6‑15] In a previous study, we found that 
epigallocatechin‑3‑gallate (EGCG) could rapidly trap both MGO 
and GO under neutral or alkaline conditions. Our data showed 
that EGCG was more reactive than lysine and arginine in terms 
of trapping MGO or GO, indicating that EGCG has the potential 
to compete with lysine and arginine in vivo and, therefore, prevent 
the formation of AGEs. In addition, we also found that EGCG was 
more reactive at trapping MGO than the pharmaceutical agent, 
aminoguanidine, which has been shown to inhibit the formation 
of AGEs by trapping of reactive dicarbonyl compounds in vivo.[16]
We have purified three major products from the reaction be-
tween EGCG and MGO at a 3:1 mole ratio. Their structures were 
identified as two mono‑MGO adducts and one di‑MGO adduct of 
EGCG with the MGO conjugated at positions 6 and 8 of the EGCG 
A‑ring [Figure 1]. Our results clearly indicate that the major active 
site of EGCG is at positions 6 and 8 of the A‑ring and that the gallate 
ring does not play an important role in the trapping of reactive dicar-
Figure 1. Adducts of methylglyoxal and epigallocathin‑3‑gallate
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bonyl species. The slightly alkaline pH can increase the nucleophilic-
ity at positions 6 and 8 of the A‑ring of EGCG, facilitating the addition 
of MGO at these two positions to form mono‑ and di‑MGO adducts.
Besides EGCG, catechin, epicatechin, theaflavin,[6] proanthocy-
anidins,[9] phloretin, phloridzin,[10] genistein,[12] curcumin,[14] and a stil-
bene glucoside from Polygonum multiforum Thunb.[11] can effectively 
trap MGO. Therefore, these compounds represent a new group of 
1,2‑dicarbonyl scavenging agents. However, these hypotheses must 
be proven by in vitro and in vivo studies with the AGEs being ac-
curately analyzed. In addition, different from traditional views on 
drugs (most drugs elicit their effects via transient interactions with 
membrane‑spanning receptors that modulate cellular signaling 
pathways), ideally, the carbonyl scavengers should show minimal 
activity toward drug receptors, thus minimizing unwanted pharma-
cological effects. Rather, the administration of carbonyl scavengers 
should proceed in the expectation that they rapidly sequester carbonyl 
species in cells, thus blocking the adduction of macromolecules and 
any downstream damages. Whether these phenolic compounds can 
selectively perform this function also demands further study.
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